IMPACT OF RISANKIZUMAB ON INTESTINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: POST HOC ANALYSIS OF THE PHASE 3 ADVANCE, MOTIVATE, AND FORTIFY STUDIES

Walter Reinisch  ¹     Florian Rieder  ²     Vipul Jairath  ^{3, 4}     Makoto Sasaki  ⁵     Kristina Kligys  ⁶     Ezequiel Neimark     Javier Zambrano     Yafei Zhang     Jean-Frédéric Colombel  ^7    
1 Medical University of Vienna, Vienna, Austria
² Cleveland Clinic, Cleveland, United States
³ University Hospital, London, Canada
⁴ Western University, London, Canada
⁵ Aichi Medical University School of Medicine, Nagakute, Japan
⁶ AbbVie Inc., North Chicago, United States
⁷ Icahn School of Medicine at Mount Sinai, New York, United States

Topic
Endoscopy, IBD

Session
Hit the road JAK: Part 1

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)